Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.83 |
| ▸ | EGFR | P00533 | 4/20 | 0.81 |
| ▸ | ITK | Q08881 | 3/20 | 0.81 |
| ▸ | LCK | P06239 | 2/20 | 0.81 |
| ▸ | TEC | P42680 | 3/20 | 0.80 |
| ▸ | BMX | P51813 | 3/20 | 0.80 |
| ▸ | TXK | P42681 | 2/20 | 0.80 |
| ▸ | LYN | P07948 | 2/20 | 0.80 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.80 |
| ▸ | FLT3 | P36888 | 2/20 | 0.80 |
| ▸ | BLK | P51451 | 2/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.80 |
| ▸ | LATS1 | O95835 | 1/20 | 0.80 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.80 |
| ▸ | ABL1 | P00519 | 1/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.80 |
| ▸ | FYN | P06241 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614537 | 1.00 | BTK (0.83) | BTKEGFRITKLCKTEC | |
| SCHEMBL23226152 | 1.00 | BTK (0.83) | BTKEGFRITKLCKTEC | |
| SCHEMBL19590157 | 0.95 | BTK (0.80) | BTKEGFRITKLCKTEC | |
| SCHEMBL16931733 | 0.93 | BTK (0.85) | BTKEGFRITKLCKTEC | |
| SCHEMBL18095743 | 0.93 | BTK (0.85) | BTKEGFRITKLCKTEC | |
| SCHEMBL27210186 | 0.92 | BTK (0.85) | BTKEGFRITKLCKTEC | |
| SCHEMBL27230444 | 0.92 | BTK (0.85) | BTKEGFRITKLCKTEC | |
| SCHEMBL5801655 | 0.91 | BTK (0.71) | BTKEGFRITKLCKTEC | |
| SCHEMBL15613464 | 0.91 | BTK (0.73) | BTKEGFRITKLCKTEC | |
| SCHEMBL17951599 | 0.91 | BTK (0.79) | BTKEGFRITKLCKTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023137182-A1 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS BASED ON BTK OCCUPANCY & RESYNTHESIS RATE | TELIOS PHARMA INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3248979-B1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INST PHYSICAL SCI CAS (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10946008-B2 | Treatment of pemphigus | PRINCIPIA BIOPHARMA INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200397895-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS LLC (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200101059-A1 | TREATMENT OF PEMPHIGUS | PRINCIPIA BIOPHARMA INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-20200039981-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-06 | — | — | US | disclosed |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-23 | — | — | US | disclosed |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2018-02-01 | — | — | US | disclosed |
| EP-2561875-A2 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560007-A1 | Identification of bruton's tyrosine kinase inhibitors | Pharmacyclics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548558-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2543375-A1 | Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2393816-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011046964-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046964-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | FLT3, FLT1, FGFR1 | BTK 32/4885EGFR 160/4885ITK 408/4885 |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 947/4885ITK 390/4885 |
| US-20200101059-A1 | TREATMENT OF PEMPHIGUS | BTK, PRKACA, PRKDC | BTK 1/4885EGFR 628/4885ITK 370/4885 |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | BTK, LYN, SYK | BTK 1/4885EGFR 985/4885ITK 328/4885 |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | BTK 2/4885EGFR 1605/4885ITK 748/4885 |
| US-10946008-B2 | Treatment of pemphigus | BTK, PRKACA, PRKDC | BTK 1/4885EGFR 708/4885ITK 332/4885 |
| US-20200039981-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR | BTK, SYK, LYN | BTK 1/4885EGFR 678/4885ITK 83/4885 |
| US-20200397895-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | BTK, LCK, LYN | BTK 1/4885EGFR 544/4885ITK 97/4885 |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | BTK 35/4885EGFR 221/4885ITK 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.